|Table of Contents|

Advances in risk factors and management strategies of checkpoint inhibitor pneumonitis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 04
Page:
770-774
Research Field:
Publishing date:

Info

Title:
Advances in risk factors and management strategies of checkpoint inhibitor pneumonitis
Author(s):
WEN Yanping1; XIAO Haiwei2; SHEN Liping1; YIN Juhua1; LIU Lingshuang1
1.Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;2.Shenshan Central Hospital,Sun Yat-sen Memorial Hospital of Sun Yat-sen University,Guangdong Shanwei 516600,China.
Keywords:
checkpoint inhibitor pneumonitis; immune-related adverse events; risk factors; review
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.04.034
Abstract:
In recent years,with the wide application of immune checkpoint inhibitors in tumor treatment,immune-related adverse events have gradually attracted people's attention.Checkpoint inhibitor pneumonitis(CIP)is a relatively rare immunotherapy related pulmonary toxicity and one of the important causes of immune checkpoint inhibitor related death.Actively explore the relevant risk factors of CIP and identify the high-risk groups of CIP,which is conducive to the early diagnosis and timely treatment of CIP.Therefore,this paper reviews the research progress on risk factors and management strategies of CIP,in order to improve the clinicians' understanding of this adverse event.

References:

［1］KENNEDY LB,SALAMA AKS.A review of cancer immunotherapy toxicity［J］.CA Cancer J Clin,2020,70(2):86-104.
［2］MICHOT JM,BIGENWALD C,CHAMPIAT S,et al.Immune-related adverse events with immune checkpoint blockade:A comprehensive review［J］.Eur J Cancer,2016,54:139-148.
［3］BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.N Engl J Med,2015,373(2):123-135.
［4］FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):A multicentre,open-label,phase 2 randomised controlled trial［J］.Lancet,2016,387(10030):1837-1846.
［5］RIZVI NA,MAZIERES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate 063):A phase 2,single-arm trial［J］.Lancet Oncol,2015,16(3):257-265.
［6］WANG DY,SALEM JE,COHEN JV,et al.Fatal toxic effects associated with immune checkpoint inhibitors:A systematic review and meta-analysis［J］.JAMA Oncol,2018,4(12):1721-1728.
［7］WANG H,GUO X,ZHOU J,et al.Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis［J］.Thorac Cancer,2020,11(1):191-197.
［8］LI M,SPAKOWICZ D,ZHAO S,et al.Brief report:Inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer［J］.Cancer Immunol Immunother,2020,69(11):2403-2408.
［9］CHO JY,KIM J,LEE JS,et al.Characteristics,incidence,and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer［J］.Lung Cancer,2018,125:150-156.
［10］YAMAGUCHI T,SHIMIZU J,HASEGAWA T,et al.Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors:A retrospective analysis［J］.BMC Cancer,2021,21(1):924.
［11］DELAUNAY M,CADRANEL J,LUSQUE A,et al.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients［J］.Eur Respir J,2017,50(2):1700050.
［12］SURESH K,VOONG KR,SHANKAR B,et al.Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy:Incidence and risk factors［J］.J Thorac Oncol,2018,13(12):1930-1939.
［13］SUN Z,WANG S,DU H,et al.Immunotherapy-induced pneumonitis in non-small cell lung cancer patients:current concern in treatment with immune-check-point inhibitors［J］.Invest New Drugs,2021,39(3):891-898.
［14］KHUNGER M,RAKSHIT S,PASUPULETI V,et al.Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer:A systematic review and meta-analysis of trials［J］.Chest,2017,152(2):271-281.
［15］ZHANG C,GAO F,JIN S,et al.Checkpoint inhibitor pneumonitis in Chinese lung cancer patients:Clinical characteristics and risk factors［J］.Ann Palliat Med,2020,9(6):3957-3965.
［16］TONE M,IZUMO T,AWANO N,et al.High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer［J］.Thorac Cancer,2019,10(10):2006-2012.
［17］NISHINO M,GIOBBIE-HURDER A,HATABU H,et al.Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer:A systematic review and meta-analysis［J］.JAMA Oncol,2016,2(12):1607-1616.
［18］MA K,LU Y,JIANG S,et al.The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer:A meta-analysis［J］.Front Pharmacol,2018,9:1430.
［19］KANAI O,KIM YH,DEMURA Y,et al.Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease［J］.Thorac Cancer,2018,9(7):847-855.
［20］SHIBAKI R,MURAKAMI S,MATSUMOTO Y,et al.Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody［J］.Cancer Immunol Immunother,2020,69(1):15-22.
［21］GALANT-SWAFFORD J,TROESCH A,TRAN L,et al.Landscape of immune-related pneumonitis in cancer patients with asthma being treated with immune checkpoint blockade［J］.Oncology,2020,98(2):123-130.
［22］SUL J,BLUMENTHAL GM,JIANG X,et al.FDA approval summary:Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1［J］.Oncologist,2016,21(5):643-650.
［23］CUI P,LIU Z,WANG G,et al.Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy:A case-control study［J］.Cancer Med,2018,7(8):4115-4120.
［24］KHOJA L,DAY D,WEI-WU CHEN T,et al.Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:A systematic review［J］.Ann Oncol,2017,28(10):2377-2385.
［25］CHAN KK,BASS AR.Autoimmune complications of immunotherapy:Pathophysiology and management［J］.BMJ,2020,369:m736.
［26］PILLAI RN,BEHERA M,OWONIKOKO TK,et al.Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer:A systematic analysis of the literature［J］.Cancer,2018,124(2):271-277.
［27］XIAO Y,YU S,ZHU B,et al.RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance［J］.J Exp Med,2014,211(5):943-959.
［28］AKBARI O,STOCK P,SINGH AK,et al.PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions［J］.Mucosal Immunol,2010,3(1):81-91.
［29］CHEN DS,IRVING BA,HODI FS.Molecular pathways:Next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1［J］.Clin Cancer Res,2012,18(24):6580-6587.
［30］FUKIHARA J,SAKAMOTO K,KOYAMA J,et al.Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors［J］.Clin Lung Cancer,2019,20(6):442-450.
［31］DA L,TENG Y,WANG N,et al.Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer:A meta-analysis of randomized controlled trials［J］.Front Pharmacol,2020,10:1671.
［32］ZHANG B,WU Q,ZHOU YL,et al.Immune-related adverse events from combination immunotherapy in cancer patients:A comprehensive meta-analysis of randomized controlled trials［J］.Int Immunopharmacol,2018,63:292-298.
［33］SU Q,ZHU EC,WU JB,et al.Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors:A systematic review and meta-analysis［J］.Front Immunol,2019,10:108.
［34］NAIDOO J,WANG X,WOO KM,et al.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy［J］.J Clin Oncol,2017,35(7):709-717.
［35］HELLMANN MD,RIZVI NA,GOLDMAN JW,et al.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer(CheckMate 012):Results of an open-label,phase 1,multicohort study［J］.Lancet Oncol,2017,18(1):31-41.
［36］HELLMANN MD,CIULEANU TE,PLUZANSKI A,et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］.N Engl J Med,2018,378(22):2093-2104.
［37］READY N,HELLMANN MD,AWAD MM,et al.First-line nivolumab plus ipilimumab inadvanced non-small-cell lung cancer(CheckMate 568):Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers［J］.J Clin Oncol,2019,37(12):992-1000.
［38］ASHER N,MAROM EM,BEN-BETZALEL G,et al.Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors［J］.Oncologist,2019,24(5):640-647.
［39］PAZ-ARES L,LUFT A,VICENTE D,et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer［J］.N Engl J Med,2018,379(21):2040-2051.
［40］HUANG Y,FAN H,LI N,et al.Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors:Systematic review and network meta-analysis［J］.Cancer Med,2019,8(5):2664-2674.
［41］SOCINSKI MA,JOTTE RM,CAPPUZZO F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC［J］.N Engl J Med,2018,378(24):2288-2301.
［42］SHAVERDIAN N,LISBERG AE,BORNAZYAN K,et al.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer:A secondary analysis of the KEYNOTE-001 phase 1 trial［J］.Lancet Oncol,2017,18(7):895-903.
［43］LIN SH,LIN Y,MOK I,et al.Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer［J］.J Clin Oncol,2019,37(15 Suppl):8512.
［44］VOONG KR,HAZELL SZ,FU W,et al.Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer［J］.Clin Lung Cancer,2019,20(4):e470-e479.
［45］赫捷,李进,程颖,等.中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南［M］.北京:人民卫生出版社,2021:71-74. HE J,LI J,CHENG Y,et al.Chinese society of clinical oncology(CSCO)guidelines for toxicity management related to immune checkpoint inhibitors［M］.Beijing:People Health Publishing House,2021:71-74.
［46］THOMPSON JA,SCHNEIDER BJ,BRAHMER J,et al.NCCN guidelines insights:Management of immunotherapy-related toxicities,version 1.2020［J］.J Natl Compr Canc Netw,2020,18(3):230-241.
［47］王汉萍,郭潇潇,周佳鑫,等.免疫检查点抑制剂相关肺炎的临床诊治建议［J］.中国肺癌杂志,2019,22(10):621-626. WANG HP,GUO XX,ZHOU JX,et al.Clinical diagnosis and treatment recommendations for the pneumonitis associated with immune checkpoint inhibitor［J］.Chinese Journal of Lung Cancer,2019,22(10):621-626.
［48］ANDRUSKA N,MAHAPATRA L,HEBBARD C,et al.Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy［J］.BMJ Case Rep,2018,2018:bcr2018225937.
［49］WANG H,ZHAO Y,ZHANG X,et al.Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis:A single-institution retrospective study［J］.Cancer Med,2021,10(1):188-198.
［50］PETRI CR,PATELL R,BATALINI F,et al.Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin:Case report and reviewof the literature［J］.Respir Med Case Rep,2019,27:100834.

Memo

Memo:
上海市自然科学基金资助项目（编号：21ZR1463700）
Last Update: 1900-01-01